BRE is already approved for clinical use in the treatment of certain CD30-expressing lymphomas [30], and this makes its use attractive for the development of clinical-grade methods to eliminate residual undifferentiated CD30+ iPSCs [31]. This evidence concerns the gene TNFRSF8 and lymphoma.